$76.65
6.28% today
Nasdaq, Feb 28, 05:20 pm CET
ISIN
US89377M1099
Symbol
TMDX

TransMedics Group, Inc. Stock price

$72.12
+11.05 18.09% 1M
-103.99 59.05% 6M
+9.77 15.67% YTD
-16.59 18.70% 1Y
+53.60 289.42% 3Y
+55.98 346.84% 5Y
+56.12 350.75% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.64 2.22%
ISIN
US89377M1099
Symbol
TMDX
Sector

Key metrics

Market capitalization $2.42b
Enterprise Value $2.61b
P/E (TTM) P/E ratio 77.27
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.50
P/S ratio (TTM) P/S ratio 6.03
P/B ratio (TTM) P/B ratio 11.53
Revenue growth (TTM) Revenue growth 109.09%
Revenue (TTM) Revenue $401.09m
EBIT (operating result TTM) EBIT $31.46m
Free Cash Flow (TTM) Free Cash Flow $-120.51m
Cash position $330.09m
EPS (TTM) EPS $0.93
P/E forward 77.06
P/S forward 5.76
EV/Sales forward 6.20
Short interest 40.34%
Show more

Is TransMedics Group, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

TransMedics Group, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

7x Buy
70%
3x Hold
30%

Analyst Opinions

10 Analysts have issued a TransMedics Group, Inc. forecast:

Buy
70%
Hold
30%

Financial data from TransMedics Group, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
401 401
109% 109%
100%
- Direct Costs 163 163
152% 152%
41%
238 238
87% 87%
59%
- Selling and Administrative Expenses 138 138
38% 38%
34%
- Research and Development Expense 50 50
62% 62%
13%
49 49
1,214% 1,214%
12%
- Depreciation and Amortization 18 18
176% 176%
4%
EBIT (Operating Income) EBIT 31 31
389% 389%
8%
Net Profit 33 33
191% 191%
8%

In millions USD.

Don't miss a Thing! We will send you all news about TransMedics Group, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransMedics Group, Inc. Stock News

Neutral
Seeking Alpha
about 15 hours ago
TransMedics Group, Inc. (NASDAQ:TMDX ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenhe...
Positive
The Motley Fool
about 18 hours ago
TransMedics Group (TMDX -2.22%), a leader in organ transplant technology, released its fourth-quarter results on Feb. 27. The company reported diluted earnings per share (EPS) of $0.19, outpacing the $0.16 forecast by analysts, and revenue of $121.6 million exceeded the $109 million estimate.
Neutral
PRNewsWire
about 19 hours ago
NEW YORK , Feb. 27, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of TransMedics Group, Inc. (NASDAQ: TMDX) between February 28, 2023 and January 10, 2025, both dates inclusive (the "Class Period"), of the important April 15, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purcha...
More TransMedics Group, Inc. News

Company Profile

TransMedics Group, Inc. is a commercial stage medical technology company, which engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in October 2018 and is headquartered in Andover, MA.

Head office United States
CEO Waleed Hassanein
Employees 584
Founded 1998
Website www.transmedics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today